Clinical Trial Detail

NCT ID NCT03035630
Title Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Guru Sonpavde
Indications

clear cell renal cell carcinoma

Therapies

Avelumab

Sunitinib

Age Groups: adult senior

No variant requirements are available.